Benperidol
Benperidol structure
|
Common Name | Benperidol | ||
|---|---|---|---|---|
| CAS Number | 2062-84-2 | Molecular Weight | 381.44 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H24FN3O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
|
Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates.
Eur. J. Nucl. Med. Mol. Imaging 35(4) , 771-8, (2008) N-([(11)C]methyl)benperidol ([(11)C]NMB) can be used for positron emission tomography (PET) measurements of D(2)-like dopamine receptor binding in vivo. We report the absorbed radiation dosimetry of i.v.-administered (11)C-NMB, a critical step before applying... |
|
|
Radiation dosimetry of [18F] (N-methyl)benperidol as determined by whole-body PET imaging of primates.
Nucl. Med. Biol. 24(4) , 311-8, (1997) Radiation absorbed doses due to IV administration of [18F](N-methyl) benperidol ([18F]NMB) were estimated by whole-body PET imaging of nonhuman primates. Time-activity curves were obtained for nine compartments (striatum, eyes, heart, lungs, liver, gallbladde... |
|
|
Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.
Nucl. Med. Biol. 35(3) , 335-41, (2008) Positron emission tomography measurements of dopaminergic D2-like receptors may provide important insights into disorders such as Parkinson's disease, schizophrenia, dystonia and Tourette's syndrome. The positron emission tomography (PET) radioligand [18F](N-... |
|
|
[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Psychiatry Res. 75(2) , 103-14, (1997) [123I]Iodobenzamide (IBZM) is an iodine-labeled dopamine receptor ligand and can be used to visualize brain D2 receptors in humans with single photon emission computerized tomography (SPECT). The ratio of striatal IBZM uptake to uptake in frontal cortex (ST/F... |
|
|
[Effect of activation tasks on acute neuroleptic-induced akathisia].
Nervenarzt 71(1) , 30-7, (2000) In this study, we investigated experimentally the effects of different activation procedures on both motor and psychic symptoms in of 11 in-patients with acute neuroleptic-induced akathisia using the Hillside and Barnes akathisia rating scales and videotape r... |
|
|
[The neuroleptic malignant syndrome].
Dtsch. Med. Wochenschr. 120(50) , 1739-42, (1995) A 22-year-old oligophrenic patient had on several occasions over several months been given various neuroleptics (haloperidol, benperidol, levomepromazine) for exacerbations of paranoid schizophrenia. For a few days before hospitalization he had become quiet a... |
|
|
[Leukopenia associated with butyrophenones. A successful treatment of psychoses with pulsed administration of neuroleptics].
Nervenarzt 70(9) , 838-41, (1999) In the monotherapeutic treatment of an acute schizophrenic psychoses with butyrophenones (haloperidol and benperidol) we saw immediate leucopenic reactions when the medication was given every day. In literature the risk of butyrophenone-induced blood dyscrasi... |
|
|
[D2-dopamine receptor upregulation and treatment response under neuroleptic therapy].
Fortschr. Neurol. Psychiatr. 68 Suppl 1 , S42-5, (2000) Animal and post mortem studies indicate that neuroleptic therapy may induce D2-dopamine receptor upregulation in the basal ganglia. To address this phenomenon in a clinical study, we investigated the D2-dopamine receptor binding in 15 DSM-III-R schizophrenics... |
|
|
Benperidol for schizophrenia.
Cochrane Database Syst. Rev. (2) , CD003083, (2005) Benperidol is a relatively old antipsychotic drug that has been marketed since 1966. It has been used in Germany for 30 years, but is also available in Belgium, Greece, Italy, the Netherlands and the UK. Benperidol is a butyrophenone antipsychotic, with the h... |
|
|
Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol.
J. Clin. Psychopharmacol. 24(1) , 97-8, (2004)
|